Company intelligence / Profile preview

Genascence Corporation

Palo Alto, California, United Statesgenascence.com ↗
Ownership
Private
Development stage
Phase 1
01

Overview

GNSC-001 is currently in Phase 1b clinical trials for knee osteoarthritis. Pre-clinical studies showed a single treatment lasted beyond one year and improved both symptoms and joint structure in a large animal model.

Therapeutic areas
Rheumatology
Modalities
Gene therapy
Industry
Biotech
02

Drug pipeline

1 asset

GNSC-001

3
03

Partnerships

California Institute for Regenerative Medicine (funding partner)

Beyond the preview

Go deeper on Genascence Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genascence Corporation.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call